405 related articles for article (PubMed ID: 15189749)
1. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
Stratton CW; Brown SD
Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
Brown SD; Rybak MJ
J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i7-15. PubMed ID: 15265831
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.
Doern GV; Brown SD
J Infect; 2004 Jan; 48(1):56-65. PubMed ID: 14667792
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000).
Reinert RR; Rodloff AC; Halle E; Baer W; Beyreiss B; Seifert H; Wichelhaus TA; Maass M; Mehl M
Chemotherapy; 2004 Jun; 50(3):143-51. PubMed ID: 15272227
[TBL] [Abstract][Full Text] [Related]
5. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
Felmingham D
J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
Kohno S; Hoban D;
J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001.
Waites K; Brown S
South Med J; 2003 Oct; 96(10):974-85. PubMed ID: 14570341
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
Sunakawa K; Farrell DJ
Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316
[TBL] [Abstract][Full Text] [Related]
9. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).
Mendes C; Marin ME; Quiñones F; Sifuentes-Osornio J; Siller CC; Castanheira M; Zoccoli CM; López H; Súcari A; Rossi F; Angulo GB; Segura AJ; Starling C; Mimica I; Felmingham D
Braz J Infect Dis; 2003 Feb; 7(1):44-61. PubMed ID: 12807691
[TBL] [Abstract][Full Text] [Related]
11. [Activity of telithromycin and other oral antibiotics against respiratory tract pathogens with acquired mechanisms of resistance].
Gómez-Garcés JL; Alós JI; Hernáiz C; Gómez C
Enferm Infecc Microbiol Clin; 2004; 22(6):323-7. PubMed ID: 15228898
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-5 (1999-2004).
Inoue M; Farrell DJ; Kaneko K; Akizawa K; Fujita S; Kaku M; Igari J; Yamaguchi K; Yamanaka K; Murase M; Asari S; Hirakata Y; Baba H; Itaha H
Microb Drug Resist; 2008 Jun; 14(2):109-17. PubMed ID: 18500920
[TBL] [Abstract][Full Text] [Related]
13. PROTEKT 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan.
Inoue M; Kohno S; Kaku M; Yamaguchi K; Igari J; Yamanaka K
Int J Infect Dis; 2005 Jan; 9(1):27-36. PubMed ID: 15603993
[TBL] [Abstract][Full Text] [Related]
14. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Peric M; Browne FA; Jacobs MR; Appelbaum PC
Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
[TBL] [Abstract][Full Text] [Related]
15. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin.
Felmingham D; Reinert RR; Hirakata Y; Rodloff A
J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():25-37. PubMed ID: 12239226
[TBL] [Abstract][Full Text] [Related]
16. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.
Low DE; Brown S; Felmingham D
Clin Microbiol Infect; 2004 Jan; 10(1):27-36. PubMed ID: 14706083
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003-2004).
Blasi F; Farrell DJ; Dubreuil L
Diagn Microbiol Infect Dis; 2009 Mar; 63(3):302-8. PubMed ID: 19135821
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-3 (1999-2002).
Inoue M; Kaneko K; Akizawa K; Fujita S; Kaku M; Igari J; Yamaguchi K; Kohno S; Yamanaka K; Iinuma Y; Murase M; Yokoyama T; Asari S; Hirakata Y
J Infect Chemother; 2006 Feb; 12(1):9-21. PubMed ID: 16506084
[TBL] [Abstract][Full Text] [Related]
19.
Flamm RK; Rhomberg PR; Sader HS
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971877
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
Walsh F; Carnegy F; Willcock J; Amyes S
J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
